Finance

Lists
BNTX:NASDAQ
BioNTech SE - ADR
95,73 $
-1,96%
(-1,91) 1D
95,73 $
0,00% (0,00)
After hours
Closed: 6 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BNTX...
Open
99,49 $
High
100,02 $
Low
95,31 $
Mkt. cap
23,87 млрд
Avg. vol.
1,04 млн
Volume
882,70 м.
52-wk high
123,98 $
52-wk low
79,52 $
EPS
-7,53 $
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 мың
Open
99,49 $
High
100,02 $
Low
95,31 $
Mkt. cap
23,87 млрд
Avg. vol.
1,04 млн
Volume
882,70 м.
52-wk high
123,98 $
52-wk low
79,52 $
EPS
-7,53 $
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 мың
News stories
From web sources and news partners
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR
CEO-
Employees7,81 мың
Founded2008
Headquarters-
Sector-
Analyst ratings
Based on 14 analysts giving stock ratings to BNTX in the past 3 months
Strong buy
Buy
11
Hold
3
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for BNTX in the last 3 months.
Highest
Current 95,73 $
140,00 $ (+46,24%)
Average
126,85 $ (+32,51%)
Lowest
96,00 $ (+0,28%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
136,00 $
+42,1%
10/06/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
115,00 $
+20,1%
10/05/2026
Jeffrey Walch
Bernstein
Hold
Maintained
96,00 $
+0,3%
09/25/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
140,00 $
+46,2%
09/24/2026
David Dai
UBS
Buy
Maintained
135,00 $
+41%
09/16/2026
Harry Gillis
Berenberg Bank
Buy
Maintained
140,00 $
+46,2%
09/15/2026
Akash Tewari
Jefferies
Buy
Maintained
138,00 $
+44,2%
09/15/2026
Evan Seigerman
BMO Capital
Hold
Maintained
105,00 $
+9,7%
09/14/2026
Asad Haider
Goldman Sachs
Buy
Maintained
127,00 $
+32,7%
09/14/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
122,00 $
+27,4%
09/14/2026
Geoff Meacham
Citi
Buy
Reiterated
125,00 $
+30,6%
08/31/2026
Emmanuel Papadakis
Deutsche Bank
Buy
Maintained
140,00 $
+46,2%
08/26/2026
Jessica Fye
J.P. Morgan
Hold
Maintained
-
-
08/19/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
130,00 $
+35,8%
08/05/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
140,00 $
+46,2%
08/05/2026
Unknown Analyst
Bernstein
Hold
Maintained
-
-
06/01/2026
Unknown Analyst
J.P. Morgan
Hold
Maintained
100,00 $
+4,5%
05/20/2026
Yaron Werber
TD Cowen
Hold
Maintained
94,00 $
-1,8%
05/05/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
130,00 $
+35,8%
04/27/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
155,00 $
+61,9%
03/13/2026
William Maughan
Clear Street
Buy
Reiterated
167,00 $
+74,4%
03/11/2026
Daina Graybosch
Leerink Partners
Hold
Downgraded
113,00 $
+18%
02/02/2026
Last report
2026 ж. 04 там.
Fiscal period
Q2 2026
EPS / Est. (EUR)
-2,22 € / -2,08 €
-6,80%miss
Revenue / Est. (EUR)
105,60 млн / 155,71 млн
-32,18%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
1,52 млрд
907,40 млн
118,10 млн
105,60 млн
Cost of goods sold
148,30 млн
302,80 млн
71,40 млн
97,00 млн
Cost of revenue
148,30 млн
302,80 млн
71,40 млн
97,00 млн
Research and development expenses
564,80 млн
505,40 млн
557,00 млн
477,10 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
148,50 млн
217,90 млн
150,80 млн
197,80 млн
Operating expense
1,40 млрд
907,20 млн
727,70 млн
860,40 млн
Total operating expenses
1,55 млрд
1,21 млрд
799,10 млн
957,40 млн
Operating income
-33,00 млн
-302,60 млн
-681,00 млн
-851,80 млн
Other non operating income
96,80 млн
-173,80 млн
42,10 млн
23,80 млн
EBT including unusual items
24,70 млн
-227,40 млн
-568,10 млн
-858,70 млн
EBT excluding unusual items
40,70 млн
-206,50 млн
-567,80 млн
-777,70 млн
Income tax expense
53,40 млн
77,60 млн
-36,20 млн
-37,90 млн
Effective tax rate
216,19%
-34,12%
6,37%
4,41%
Other operating expenses
690,30 млн
183,90 млн
19,90 млн
185,50 млн
Net income
-28,70 млн
-305,00 млн
-531,90 млн
-820,80 млн
Net profit margin
-1,89%
-33,61%
-450,38%
-777,27%
Earnings per share
-0,12
-0,33
-1,95
-2,22
Interest and investment income
-
265,50 млн
61,70 млн
66,40 млн
Interest expense
-2,60 млн
-
-4,00 млн
-3,50 млн
Net interest expenses
-2,60 млн
265,50 млн
57,70 млн
62,90 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
91,20 млн
-266,95 млн
-559,70 млн
-585,70 млн
Gain or loss from assets sale
-1,30 млн
-800,00 м.
-100,00 м.
-900,00 м.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары